MFN News Items - Page 4 of 20

Xintela presents new preclinical results of XSTEM treatment on would healing and skin regeneration at cell therapy conference

Xintela is presenting today new preclinical data with the company’s stem cell product XSTEM® for wound healing and skin regeneration at the International Society for Cell & Gene Therapy (ISCT) Europe 2024, in Gothenburg. The results are presented both as a poster and as an oral presentation. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected […]

Xintela AB Interim Report January – June 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]

Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients

Xintela and Region Östergötland have signed an agreement where Xintela will develop and establish a GMP process to isolate and quality assure autologous (patient-own) skin cells for the treatment of burns. The agreement is worth SEK 3.6 million. The process will form the basis for an approval from the Medical Products Agency for the Burn […]

Xintela extends clinical study with XSTEM on knee osteoarthritis patients

Xintela has implemented a change to the clinical study protocol where the follow-up time for the patients at the highest dose level has been extended by 6 months to obtain additional efficacy data for XSTEM® 24 months after dosing. An interim analysis of study data up to 18 months post dosing for all dose levels […]

Xintelling, No. 3 2024

Read Xintela’s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]

Xintela AB Interim Report January – March 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2024 for the groupIncome amounted to TSEK 299 (0).Loss before tax totalled TSEK 11,372 (loss: 15,843).Loss per share was SEK 0.02 (loss: 0.05). First quarter 2024 for the parent companyIncome amounted to TSEK 299 (0).Loss before […]

Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses

Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]

Xintela AB publishes Annual Report 2023

Xintela AB (publ) announces that the company’s annual report for 2023 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]

Xintelling, No. 2 2024